Authors
Latest:
Semaglutide Shows Promise for MASH Resolution, Severe Fibrosis: Naim Alkhouri, MDNaim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment landscape for patients with metabolic dysfunction-associated steatohepatitis (MASH) and severe fibrosis.
Latest:
Determinants of ICS Therapy Adherence in Patients With AsthmaThis study describes determinants affecting disease control and inhaled glucocorticosteroid therapy adherence for patients with asthma in western China.
Latest:
Emerging Multiple Myeloma Data and Future Outlook From ASCO 2025Panelists discuss how upcoming ASCO presentations will focus on long-term CAR T-cell therapy outcomes showing potential cure plateaus, minimal residual disease (MRD)–guided treatment escalation/de-escalation strategies, tri-specific antibodies, and the economic value of using MRD negativity to guide maintenance therapy discontinuation decisions.
Latest:
AUA 2024: Disrupting the Field of UrologySpeakers at the 2024 American Urological Association (AUA) annual meeting highlighted the innovations and advancements that are pushing the field of urology forward.
Latest:
MFN Drug Pricing: Risks to Access, Affordability, and Innovation in Health CareAdam Colborn, JD, associate vice president of congressional affairs at AMCP, shares insights on the impact of the Most Favored Nation drug pricing order when it comes to access, affordability, and innovations in US health care.
Latest:
Adverse Drug Effects Across Patients With Heart Failure: A Systematic ReviewThis systematic literature review reports incidence of adverse drug effects associated with guideline-directed medical therapy for patients with heart failure with reduced ejection fraction.
Latest:
Medicare Advantage in Rural Areas: Implications for Hospital SustainabilityThis retrospective cohort study of rural hospitals found that Medicare Advantage penetration increased substantially from 2008 to 2019 and was associated with greater hospital sustainability.
Latest:
Rituximab Reference vs Biosimilar Utilization for Oncology vs Nononcology IndicationsReporting on the real-world utilization of reference rituximab and its biosimilars can help show prescribing habits and reveal cost-saving opportunities.
Latest:
Patient-Centered Communication and Outcomes in Heart FailureAmong community patients living with heart failure, excellent and good patient-centered communication was associated with a reduced risk of death.
Latest:
Assertive Community Treatment for Complex and Costly PatientsAssertive community treatment, a strongly evidence-based practice for delivering care to individuals with schizophrenia and low health care engagement, is applicable to disengaged, medically complex patients.
Latest:
CAR T and Bispecifics Pose Different Challenges in Blood Cancer Treatment: Ravi Vij, MD, MBARavi Vij, MD, MBA, discusses the logistical differences between administering CAR T-cell therapy and bispecific antibodies, and how emerging CAR T technologies could affect patient access.
Latest:
A Cue-to-Action Pilot Project to Increase Screening MammographyA targeted cue-to-action campaign of outreach, education, and incentive can improve uptake of screening mammography.
Latest:
Contributor: How Chronic Care Management Could Be the Great Equalizer for CareBy creating a framework for social determinants of health that explores patients’ needs and prioritizes team members’ response, specialty practices can more effectively strengthen health equity, access to care, and health outcomes.
Latest:
Increasing Medicare Annual Wellness Visits in Accountable Care OrganizationsThrough innovations increasing the ease of scheduling and the efficiency of conducting annual wellness visits (AWVs), a large Medicare accountable care organization has been able to increase AWV rates among eligible beneficiaries.
Latest:
Concluding Remarks: Impact of Alzheimer Disease, Promising Treatments in Development, and Future OutlookLooking to the future of Alzheimer disease treatment, the panel discusses key takeaways on the evolving therapeutic landscape.
Latest:
A Multistakeholder Effort in Pennsylvania to Improve the Accuracy of Reporting Fatal Drug OverdosesThe authors describe a novel training program for death certifiers in Pennsylvania, which has been designed to specifically focus on some of the main challenges in the death certification process and resulted in a useful model that can potentially be adopted by other states or municipalities.
Latest:
Long-Term Health Care Costs Following COVID-19: Implications for Pandemic PreparednessA difference-in-differences analysis of health care claims data evaluated excess health care costs in the 12 months following COVID-19 diagnosis among the general and older adult populations.
Latest:
Trends in Glucagon-Like Peptide 1 Receptor Agonist Prescribing PatternsGlucagon-like peptide 1 receptor agonists, including semaglutide, have increased in use and will continue to increase due to their effectiveness in weight loss.
Latest:
Contributor: Unlocking the Value of Unstructured Data From Continuity of Care Documents Using Medical-Grade NLPClinical-grade, expert-supported natural language processing (NLP) is valuable to payers and providers when exchanging patient information through continuity-of-care documents.
Latest:
Regulation of Provider Networks in Response to COVID-19The authors describe federal and state provider network adequacy standards and discuss how regulators should adapt these standards and accompanying monitoring processes in response to coronavirus disease 2019 (COVID-19).
Latest:
Introducing New Jersey's Premier NCI-Designated Comprehensive Cancer Care Center: Andrew Evens, DO, MBA, MScAndrew Evens, DO, MBA, MSc, deputy director for clinical services and chief physician officer, Rutgers Cancer Institute, introduces New Jersey's new state-of-the-art facilities at the Jack & Sheryl Morris Cancer Center.
Latest:
Type 2 Diabetes Patient Activation and mHealth Interventions Decreased Cardiovascular Disease RiskMobile health (mHealth) and a patient activation program could serve as a model for improving health outcomes for patients in outpatient clinical settings by decreasing atherosclerotic cardiovascular disease risk score.
Latest:
Efficient Strategies to Reduce Wait Time Between Diagnosis of Hidradenitis Suppurativa and TreatmentPanelists discuss the challenges of biologic access in hidradenitis suppurativa due to utilization management policies like step therapy, emphasizing the need for patient education, strategic planning, and leveraging resources—including clinical trials—to improve timely treatment and outcomes.
Latest:
Early SYRUS Data Highlight Safety, Efficacy of AZD0486 in Relapsed/Refractory B-Cell ALL: Ibrahim Aldoss, MDAZD0486 demonstrated encouraging safety and dose-dependent efficacy in heavily pretreated adolescent and adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL), according to early findings from the phase 1/2 SYRUS trial and Ibrahim Aldoss, MD, of City of Hope.
Latest:
Availability of Prices for Shoppable Services on Hospital Internet SitesOnly 60% of hospitals display their cash prices and 5% display their minimum negotiated charges on their public websites; many hospitals are in violation of new federal legislation.
Latest:
Comprehensive Genomic Profiling in Community OncologyRecommendations to address limitations in more widespread use of reflex testing in community oncology.
Latest:
Telehealth User Experiences During COVID-19: A Case Study of Outpatient Cardiovascular Clinics Affiliated With a Large Academic PracticeIn cardiovascular clinics during COVID-19, notable barriers to successful telehealth use included obtaining diagnostic information needed to deliver high-quality care and technology-related challenges for patients.
Latest:
Type 2 Diabetes Patient Activation and mHealth Interventions Decreased Cardiovascular Disease RiskMobile health (mHealth) and a patient activation program could serve as a model for improving health outcomes for patients in outpatient clinical settings by decreasing atherosclerotic cardiovascular disease risk score.
